ARID1A deficiency due to somatic mutations have been associated with impaired DNA damage repair in BC, thus prompting the development of synthetic lethality-based therapeutic strategies for ARID1A-mutated neoplasms (20, 21). This evidence concerns the gene ARID1A and breast cancer.